Ed Jun

Vice President, Finance

Ed Jun is a thoughtful leader who empowers and inspires his teams to deliver exceptional performance in alignment with the company’s goals. He is a seasoned finance leader with a strong life sciences background who drives decision making based on the needs of the business and analytical acumen. Mr. Jun leads the Finance & Accounting teams, as well as the Technology team at Ossium.

Before joining Ossium, Mr. Jun developed and led the Finance, Planning & Analysis team at Caribou Biosciences. As Caribou transitioned into a public company, he was instrumental in shaping new financial processes such as leading the budgeting, forecasting, board financials, and other financial analyses. Mr. Jun also led the FP&A function at Audentes Therapeutics, where he worked to integrate the company’s processes and financials into Astellas Pharmaceuticals. He also led the North America retail FP&A team at Activision Blizzard and spent 10 years at Pfizer in various commercial finance and FP&A roles. In 2016, Mr. Jun was recognized by the Asian American Business Development Center as one of the top 50 Outstanding Asian Americans in business.
Mr. Jun is a Navy surface warfare veteran and served for four years on two different Destroyers. Mr. Jun received his BS in Mechanical Engineering and his MBA in Finance, both from Cornell University.

Sagar Munjal

Chief Medical Officer, Senior Vice President

Dr. Sagar Munjal has more than twenty years of experience in drug development and product strategy and oversees Ossium’ clinical programs, pipeline, and strategy. His expertise spans clinical development (phase I-IV), clinical operations, medical affairs, R&D, and global product launches. Dr. Munjal has worked in eight therapeutic areas and has brought four products to market and successfully negotiated a complex failed phase 3 study with the FDA to achieve product approval. He has worked extensively with regulatory and government agencies, including the FDA, EMA, MHRA, ANVISA, and the DCGI. Dr. Munjal has drug development experience in small molecules, drug-device combination products, and biologics.

Dr. Munjal has managed global teams in the US, Europe, and India. He has worked with CROs of all sizes, investors, and scientific advisors.

Before joining Ossium, Dr. Munjal worked at Dr. Reddy’s Laboratories Inc (USA), and was Chief Medical Officer at Promius Pharma LLC, a wholly owned subsidiary of Dr. Reddy’s. Previously, he worked at Johnson & Johnson, Altria, and in the clinic as an investigator. Dr. Munjal has published more than 30 manuscripts related to clinical studies, presented more than 60 abstracts at various scientific meetings, and was the recipient of the 2017 Harold G. Wolff award from the American Headache Society for key scientific contributions to the migraine field. Dr. Munjal received his MD from Karnataka University Dharwad and his MS in Clinical Research and Biostatistics from Virginia Commonwealth University.

Hans Nowak

Vice President, Technical Operations

Hans Nowak II is a seasoned executive known for his leadership and expertise in manufacturing and supply chain operations, engineering, and business analytics. His strategic business experience, grounded in a robust technical foundation, has enabled him to optimize operational excellence and drive transformative growth across multiple complex, regulated industries.

At Ossium Health, Mr. Nowak leads day-to-day manufacturing, supply chain, and engineering operations, overseeing production output, product quality, and distribution. He also shapes the company’s strategic and operational vision to expand the product range, innovate for company growth, bolster manufacturing capabilities, and drive continuous competitive improvement while maintaining a safety-first and quality-always mindset.

Prior to Ossium, Mr. Nowak served as a Senior Engagement Manager at McKinsey & Company, where he led pharmaceutical and medical device companies through their most challenging operations and analytics problems. His projects ranged from heading the operational, quality, and digital transformations of manufacturing networks and sites to building product development strategies that significantly reduced development time, leading to rapid approvals of new molecular entities. Before joining McKinsey, Mr. Nowak spent over a decade in engineering and operations leadership positions in industries ranging from nuclear engineering and defense to manufacturing operations and pharma.

Mr. Nowak is a Navy submarine veteran and a graduate of the United States Naval Academy, where he received his BS in Applied Mathematics and BS in Quantitative Economics. He continued his education at MIT as a Leaders for Global Operations (LGO) Fellow and Siebel Scholar, graduating first in his class and receiving his MS in Mechanical Engineering from MIT’s School of Engineering and his MBA from the MIT Sloan School of Management. Mr. Nowak is certified in nuclear engineering, operations research, and business analytics, and he has shared his expertise by teaching courses at prestigious institutions such as IUPUI and MIT.

Mr. Nowak is a Navy submarine veteran and a graduate of the United States Naval Academy, where he received his BS in Applied Mathematics and BS in Quantitative Economics. He continued his education at MIT as a Leaders for Global Operations (LGO) Fellow and Siebel Scholar, graduating first in his class and receiving his MS in Mechanical Engineering from MIT’s School of Engineering and his MBA from the MIT Sloan School of Management. Mr. Nowak is certified in nuclear engineering, operations research, and business analytics, and he has shared his expertise by teaching courses at prestigious institutions such as IUPUI and MIT.

Kathleen Vasilopulos

Vice President, Donor Operations

Kathleen Vasilopulos is a proven operations executive, with a background in nursing, healthcare, legal consulting, business development, and organ and tissue donation. She is focused on mission-driven, life-saving healthcare initiatives. At Ossium, Ms. Vasilopulos oversees the donor ecosystem, managing relationships with recovery partners and ensuring that our donor bank continues to expand.

Prior to joining Ossium, Ms. Vasilopulos held leadership positions in healthcare and medical legal consulting. As Vice President of Hospital Development & Family Services at Donor Network West, Ms. Vasilopulos directed teams in Northern California and Nevada, significantly improving organ authorization and donation rates. At OneLegacy, the world’s largest organ, tissue, and eye procurement organization, her leadership contributed to record-breaking years for organ donation and transplantation. Ms. Vasilopulos served as Vice President of Business Development at Recruitment Specialists Inc., where she secured key contracts and managed national projects that generated millions in sales. Her career also includes successful tenures at Progressive Nursing Staffers, where she drove substantial sales and growth. Ms. Vasilopulos started her healthcare career as a Cardiovascular ICU Nurse and Team Lead. With a BSN and an MBA from the University of Illinois, as well as certifications in procurement transplant and tissue banking, she has built a reputation for exceptional leadership across various industries, consistently driving organizational growth and operational excellence.

Chip Walker-Wilson

General Counsel & Senior Vice President

Chip Walker-Wilson is the General Counsel & Senior Vice President, and he is responsible for overseeing Ossium Health’s legal and corporate governance functions.

Prior to joining Ossium Health, Mr. Walker-Wilson served as legal counsel at Cytokinetics, a clinical-stage biopharmaceutical company with development programs in the areas of cardiovascular and neurological diseases. At Cytokinetics, Mr. Walker-Wilson primarily supported the Research & Development Department, including the Clinical Operations, Non-Clinical Development, Research, Biometrics and Informatics groups. Prior to Cytokinetics, Mr. Walker-Wilson served as legal counsel at Dynavax Technologies Corporation, a biotechnology company with development programs in vaccines, cancer immunotherapies, and autoimmune and inflammatory diseases. At Dynavax, Mr. Walker-Wilson provided support across the company, including the Research & Development, Technical Operations, Corporate Governance, Business Development, Information Technology, Regulatory, Quality, Human Resources, and Medical Affairs groups. Prior to Dynavax, Mr. Walker-Wilson served as legal counsel at Abbott Laboratories. Mr. Walker-Wilson supported Abbott Diabetes Care, a medical device manufacturer that develops and sells blood glucose monitoring products. At Abbott, Mr. Walker-Wilson primarily worked with the Sales, Marketing, Strategic Partnership and Alliances, Business Development, and Customer Service groups. Prior to Abbott, Mr. Walker-Wilson worked at the law firms of Orrick, Herrington & Sutcliffe and Sheppard, Mullin, Richter & Hampton, where his practice focused primarily on corporate and securities law and finance law.

Mr. Walker-Wilson received his BA in Legal Studies (with a minor in Rhetoric) from the University of California, Berkeley and his JD from the University of California, Berkeley School of Law.